LAVA Therapeutics N.V. (Nasdaq: LVTX) has announced a major milestone under the research collaboration initiated in 2020 with Janssen Biotech, Inc., a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ). 

Janssen Biotech has selected a lead candidate specifically designed to target a tumor-associated antigen for further development in clinical settings. 

This decision opens up new avenues for LAVA Therapeutics, as it becomes eligible to receive potential development, regulatory, and commercialization milestone payments, along with tiered royalties. 

The market response has been positive, with $LVTX currently trading at $2.42 in pre-market, representing an increase of $0.52 (+27.42%).

In another noteworthy development, The Chemours Company (NYSE: CC), DuPont de Nemours, Inc. (NYSE: DD), and Corteva, Inc. (NYSE: CTVA) have reached an agreement in principle to address the PFAS-related drinking water claims of a defined class of public water systems that cater to a significant portion of the United States population. 

The comprehensive resolution involves the establishment of a settlement fund totaling $1.185 billion. Chemours will contribute 50 percent of the fund (approximately $592 million), while DuPont and Corteva will collectively contribute the remaining 50 percent, with DuPont contributing approximately $400 million and Corteva contributing around $193 million

This agreement in principle represents a significant step forward in resolving the PFAS-related drinking water claims. 

The pre-market trading figures reflect the response to this development, with $CC trading at $28.50 (+$1.39 or +5.13%), $DD at $70.03 (+$2.59 or +3.84%), and $CTVA at $54.96 (+$1.10 or +2.04%). 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)